Navigation Links
GPhA Statement on the Introduction of the Bipartisan Senate Biogenerics Consensus Bill: 'Promoting Innovation and Access to Life-Saving Medicine Act'

Companion Senate Bill Puts Patient Health and Safety and Pharmaceutical Innovation First

ARLINGTON, Va., March 26 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the bipartisan Senate introduction of the "Promoting Innovation and Access to Life-Saving Medicine Act."

"Momentum is skyrocketing for biogenerics legislation that puts patients and pharmaceutical innovation first. The legislation introduced today in the Senate and last week in the House demonstrates that life-saving biogenerics can get to patients in need sooner rather than later while also fostering competition to drive pharmaceutical innovation. We applaud Senators Chuck Schumer (D-NY), Sherrod Brown (D-OH), Susan Collins (R-ME), Mel Martinez (R-FL), Jeanne Shaheen (D-NH), Debbie Stabenow (D-MI) and David Vitter (R-LA) for their commitment to increasing access to these life-saving medicines while also ultimately reducing overall health care costs.

"This bipartisan consensus bill holds generic companies to the same quality, safety and science-based standards as brand companies when they make subsequent product changes of their biopharmaceutical medicines. This consensus bill also provides FDA with the same scientific discretion regarding approval criteria for biogenerics and biosimilars as they have for biopharmaceuticals. There should be one gold standard for science, quality and safety and this legislation provides that standard while also creating a system of market exclusivity that has allowed both the brand and generic industries to flourish together for 25 years to the benefit of consumers.

"Reducing overall health care costs while increasing access to quality care is essential to achieving real health care reform. With studies showing that biogenerics legislation will produce significant savings, it is critical that Congress act to ensure these affordable life-saving medicines get to patients in a timely manner.

"Momentum is not only growing in Congress, but across the country, with millions of Americans represented by leading consumer, business and labor organizations and AARP supporting this legislation that puts equality into the system and needed medicines into the hands of consumers.

"It's time to enact legislation that gives FDA the authority and flexibility to create a workable biogenerics approval pathway that upholds their gold standard of ensuring safety and quality. We don't need a pathway that's so filled with roadblocks that it is merely an empty promise for patients. Let's fulfill our promise to patients and to strengthening our health care system by passing the 'Promoting Innovation and Access to Life-Saving Medicine Act'."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit

SOURCE Generic Pharmaceutical Association
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... ... 2015 , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has ... The order will be from the China Disabled Persons’ Federation, a central government association, ... solution for children and adults suffering from severe and profound hearing loss . ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced ... (ATP) status from Cisco. This designation recognizes Tympani as having fulfilled the training ... solutions targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... UPPSALA, Sverige, December 1, 2015 ... Breast Cancer Study Group (IBCSG, Bern ... att ingå i en klinisk studie av palbociclib, ... --> Studien, med namn PYTHIA, ... med anti-hormonella läkemedel i kombination med palbociclib, som ...
(Date:11/30/2015)... MAPLE GROVE, Minn. and BASEL, ... Upsher-Smith Laboratories, Inc. (Upsher-Smith), through its wholly-owned ... for the further development of a novel, oral small ... cell-adhesion molecule that may be effective in the treatment ... Phase II clinical development. --> ...
(Date:11/30/2015)... Dec. 1, 2015 Express Scripts (NASDAQ: ESRX ... IMMY ) to drive access to a low-cost alternative ... of toxoplasmosis that has been recently priced out of reach ... immune systems. --> --> ... leucovorin (a form of folic acid) for $1 per capsule for ...
Breaking Medicine Technology: